Industry Overview
The Global Cold Plasma Market is likely to be valued at USD 1.3 billion in 2023 and is anticipated to attain USD 3.6 billion by 2030, developing at a CAGR of 12.5% concurrently for the forecast duration (by 2030). Cold plasma, also known as non-thermal plasma, is an innovative concept with extensive adoption in medical device applications. Various medical disciplines, such as cardiology, dermatology, gastroenterology, and oncology, have benefited from the technology, which is now widely utilized to aid surgery in these fields.The cold plasma technology has gained significant attention in the healthcare industry due to its potential applications in various medical fields. Cold plasma refers to a partially ionized gas that is produced at atmospheric pressure and low temperatures. It consists of a mixture of ions, electrons, reactive oxygen species, and other free radicals.
.jpg "Cold Plasma in Healthcare Market Highlights")
Cold plasma offers a wide range of uses in bioengineering and as an antibacterial treatment for food processing along with increased adoption of cold plasma in wound healing, which is boosting the cold plasma market in the healthcare sector forward. The novel adoption of cold plasma in cancer therapy is an intriguing field that is predicted to have a substantial impact on current cancer therapeutic research, propelling the cold plasma market forward.
Plasma therapy has demonstrated positive effects for coronavirus treatment as the number of COVID-19 patients has increased. Cold plasma therapy is also being promoted as a viable treatment for the continuing COVID-19 outbreak. Plasma therapy is increasingly gaining traction as it helps in treating patients suffering from coronavirus. Countries such as the United States, China, Turkey, Spain, India, and the United Kingdom are among the few that are considering plasma treatment to address the global COVID-19 crisis.
Market Segmentation
Insight by Regime Type
Based on the regime, the cold plasma in the healthcare market is divided into low-pressure cold plasma and atmospheric cold plasma. The atmospheric cold plasma dominates the market as it kills microbes without harming human tissues. Atmospheric Cold Plasma (ACP) is a technique that increases molecules, atoms, and ions' natural processes. Furthermore, it aids in treating cancer patients owing to its anti-tumour properties.
Insight by Application
Based on application, the cold plasma in the healthcare market is divided into wound healing, blood coagulation, dentistry, cancer treatment, and others. The wound healing segment dominates the cold plasma market as cold plasma can kill bacteria, including drug-resistant bacteria, and thus aids in the treatment of chronic wounds by preventing infection. It also hastens the wound healing process and prevents additional complications.
The demand for cold plasma is expected to rise as the COVID-19 crisis rises. Plasma Care, a CE-marked medical device that generates cold atmospheric plasma and was discovered to be designed for the mobile treatment of acute and chronic wounds, laid the foundation for this advancement.
Moreover, with the rising incidences of road traffic injuries, resulting in a large number of patients suffering from traumas and increased wound management cases, the implementation of cold plasma is anticipated to grow for wound healing in hospitals and healthcare facilities. Furthermore, the rising geriatric population having diabetes may have chronic wounds like foot ulcers, thus accelerating the growth of cold plasma in the healthcare market. Although many alternative wound healing therapy processes exist, cold plasma treatment is expected to be one of the most successful strategies to propel the overall segment forward.
Global Cold Plasma in Healthcare Market Report Coverage
|
Report Metric
|
Details
|
|
Historical Period
|
2018 - 2023
|
|
Base Year Considered
|
2024
|
|
Forecast Period
|
2025 - 2030
|
|
Market Size in 2023
|
U.S.D. 1.3 Billion
|
|
Revenue Forecast in 2030
|
U.S.D. 3.68 Billion
|
|
Growth Rate
|
12.5%
|
|
Segments Covered in the Report
|
By Regime Type, and By Application
|
|
Report Scope
|
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
|
|
Regions Covered in the Report
|
North America, Europe, Asia-Pacific, Middle East, and Rest of the World
|
Industry Dynamics
Growth Drivers
Cold plasma in the healthcare market is extensively used in medicinal and bioengineering fields. They are used to sanitize biomedical surfaces and treat natural tissues because of their antibacterial and bacterial characteristics. Cold plasma treatments have shown the potential to cure a variety of growth types, including lung, cerebrum, breast, and skin. The evolving applications in life sciences like treating surgical and traumatic wounds and increased commercialization will drive the growth of cold plasma in the healthcare market.
Antimicrobial Applications: Cold plasma has shown promising antimicrobial properties, effectively killing bacteria, viruses, and fungi. It can be used to sterilize medical instruments, disinfect surfaces, and treat contaminated water. The technology has the potential to reduce hospital-acquired infections and improve overall hygiene in healthcare facilities.
Wound Healing: Cold plasma has been studied for its ability to promote wound healing. When applied to wounds, it can stimulate cell migration, accelerate tissue regeneration, and reduce inflammation. It shows promise in treating chronic wounds, burns, and ulcers, providing an alternative to conventional wound care methods.
Cancer Treatment: Cold plasma has shown potential in cancer therapy, primarily through its ability to induce apoptosis (programmed cell death) in cancer cells. Researchers are exploring its use in targeted cancer therapies, including the treatment of skin cancer, breast cancer, and lung cancer. However, further research is needed to establish its efficacy and safety.
Challenges
Cold plasma techniques are capital-intensive as the equipment necessary for operation, like vacuum equipment, is expensive and requires unique operating circumstances, such as low temperatures and regulated vacuum settings, resulting in hampering the growth of the cold plasma market.
Opportunities
Cold plasma's improved efficacy in developing therapies for various forms of cancer, like lung, breast, bladder, and skin, is likely to open up numerous opportunities for the market participants during the projected period. The cold plasma technique has been proven to selectively kill cancer cells in a variety of in vitro and in vivo investigations. Plasma-induced apoptosis and the reduction of cell migratory velocity are two key properties that have improved the usage of cold plasma in cancer therapy. This aids in the localization of the damaged tissue area as well as the prevention of cancer metastasis.
Cold plasma can also be used in conjunction with chemotherapy to increase wound sterilizing, blood coagulation, and cell proliferation during wound healing. Its use enables successful medical treatment of cancer, as well as a variety of skin injuries and disorders.
Geographic Overview
North America contributes to the largest share in the cold plasma healthcare market owing to the presence of key industry players and the increased number of products having FDA approvals. Moreover, the increased adoption of technologically developed products will further accelerate the growth of cold plasma in the healthcare market in the region. There is an increased demand for plasma therapy owing to the rising cases of coronavirus.
Scientists have proven that treatments with cold atmospheric plasma at near-room temperature can kill the coronavirus on a range of surfaces in as little as 30 seconds, according to a paper published in 2020 by the ULCA Samueli School of Engineering. Their research, which was published in the journal Physics of Fluids, is the first to prove that cold plasma can disinfect surfaces infected with the SARS-CoV-2 virus, which produces COVID-19. "There is a promising opportunity for growth in the cold atmospheric plasma as a safe and effective means to stop the virus from spreading by killing it on a variety of surfaces.”
Competitive Insight
In the healthcare market, cold plasma is consolidated in nature with players strategizing via research and development activities, partnerships, agreements, collaborations, alliances, M&A, product development, etc. to expand their geographical presence and sustain themselves in the market.
US Medical Innovations, LLC is a privately-held life science and biomedical device company that is FDA-registered. USMI is committed to pushing the limits of plasma medicine by developing novel technologies for the advancement of cutting-edge medical devices that improve patient outcomes and human lives. Their product portfolio includes CANADY SURGICAL SYSTEM, CANADY PLASMA XL-1000 SMART GENERATOR, CANADY HYBRID PLASMA SCALPEL, CANADY PLASMA PROBES, and CANADY SMART OR™ STEALTH INTEGRATION SYSTEM.
Neoplasm is striving towards a new era of medicine in which the therapeutic use of cold plasma will enhance people's quality of life In Germany, almost two million people have chronic, non-healing wounds, thus there is a need to develop and extend the intriguing possibilities of cold plasma therapy. The kINPen®IND is a compact cold plasma device that works with air pressure. Under atmospheric pressure, the portable kINPen®IND can clean, disinfect, and activate surfaces.
In October 2021, The United States Patent and Trademark Office has granted a notice of allowance to US Medical Innovations, LLC (USMI) and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) to develop a system for treating respiratory infections and cancers of respiratory system with cold atmospheric plasma.
In January 2022, PLASMITEC is the trademark name for WACKER's platform for generating and producing plasmid DNA (pDNA). At the newly purchased San Diego location, the exclusive technology platform is based on decades of experience in pDNA manufacture. It can be utilized in research, clinical development, and commercial manufacturing. pDNA is the foundation for a wide range of novel therapeutic agents, and demand for these products is growing. As part of efforts to design and manufacture mRNA-based vaccines for COVID-19, demand for pDNA has risen dramatically recently.
US Medical Innovations, RELYON PLASMA GMBH, neoplasm GmbH, Europlasma NV, P2i Ltd, Wacker Chemie AG, ADTEC Plasma Technology co.,ltd., terraplasma medical GmbH (Acquired by Viromed Group), Coldplasmatech GmbH, and Apex Medical, are some of the leading businesses in the cold plasma healthcare sector.
The Cold Plasma in Healthcare Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.
Segments Covered in the Report
- By Regime Type
- Low Pressure
- Atmospheric Pressure
- By Application
- Wound Healing
- Cancer Treatment
- Dentistry
- Blood Coagulation
- Others
Region Covered in the Report
- North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
- Rest of the World (RoW)
- Brazil
- Saudi Arabia
- South Africa
- U.A.E.
- Other Countries
.png "Cold Plasma in Healthcare Market Size and Market Analysis")
